<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/49FFE305-71E4-41B1-87AC-8E58220B1F28"><gtr:id>49FFE305-71E4-41B1-87AC-8E58220B1F28</gtr:id><gtr:name>Novartis Institutes for Biomedical Research (NIBR)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/FA8A4959-62A8-4182-9EFF-78C4DD583249"><gtr:id>FA8A4959-62A8-4182-9EFF-78C4DD583249</gtr:id><gtr:name>Royal Brompton &amp; Harefield NHS Fdn Trust</gtr:name><gtr:department>Respiratory Medicine</gtr:department><gtr:address><gtr:line1>Sydney Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW3 6NP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FA8A4959-62A8-4182-9EFF-78C4DD583249"><gtr:id>FA8A4959-62A8-4182-9EFF-78C4DD583249</gtr:id><gtr:name>Royal Brompton &amp; Harefield NHS Fdn Trust</gtr:name><gtr:address><gtr:line1>Sydney Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW3 6NP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/49FFE305-71E4-41B1-87AC-8E58220B1F28"><gtr:id>49FFE305-71E4-41B1-87AC-8E58220B1F28</gtr:id><gtr:name>Novartis Institutes for Biomedical Research (NIBR)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F5ED0F87-6900-4827-A1E1-608A7AF9C6D7"><gtr:id>F5ED0F87-6900-4827-A1E1-608A7AF9C6D7</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>I</gtr:otherNames><gtr:surname>Polkey</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4CFBB3DD-7521-4EDC-AC6F-779831757C9D"><gtr:id>4CFBB3DD-7521-4EDC-AC6F-779831757C9D</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:surname>Steiner</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/70C3EDBE-4231-48AA-B709-1362B289A10B"><gtr:id>70C3EDBE-4231-48AA-B709-1362B289A10B</gtr:id><gtr:firstName>Charlotte</gtr:firstName><gtr:otherNames>Emma</gtr:otherNames><gtr:surname>Bolton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C9DF7C42-AF11-4540-A4D7-A5CAF1EC1765"><gtr:id>C9DF7C42-AF11-4540-A4D7-A5CAF1EC1765</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Moxham</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E3A2A74C-3279-4118-8679-4AA45A018811"><gtr:id>E3A2A74C-3279-4118-8679-4AA45A018811</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Kemp</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F3D4685A-A599-42C7-9F85-0865A5AB3B1D"><gtr:id>F3D4685A-A599-42C7-9F85-0865A5AB3B1D</gtr:id><gtr:firstName>William</gtr:firstName><gtr:surname>MacNee</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5AE4ADB3-2D15-4BD9-AB04-F760B7744654"><gtr:id>5AE4ADB3-2D15-4BD9-AB04-F760B7744654</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:surname>De Soyza</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9648AEBD-DCA1-4AEE-8F62-D711549B8096"><gtr:id>9648AEBD-DCA1-4AEE-8F62-D711549B8096</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Greenhaff</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1001362"><gtr:id>0D601377-6959-461A-A0BF-DD3D9DE60F57</gtr:id><gtr:title>Reducing the burden of COPD by targeting skeletal muscle mass and function. Targets and endpoints for drug development</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1001362</gtr:grantReference><gtr:abstractText>Chronic Obstructive Pulmonary disease (or emphysema and chronic bronchitis) is a family of lung diseases usually but not always caused by cigarette smoking. There is an urgent need to develop new drugs to treat this condition since existing therapies are insufficiently effective. Importantly in more advanced disease complications outside the lung become as important as the lung disease itself and in fact one of the most effective treatments, pulmonary rehabilitation (supervised exercise training) is thought to work in large part by improving the strength and function of the walking muscles; thus we believe a drug which could magnify or extend the benefit of this treatment would be every useful. Thus the aim of this work package is to bring together the groups interested this field in Great Britain with selected drug companies. Three stages of the WP are described. In the first we will assess what material is available and whether, by sharing, the consortium can achieve some ?quick wins? which will facilitate the development of drugs or ideas already known to the participants. In the second we will do some detailed studies which will relate actual rates of protein synthesis in the leg muscles to more readily accessible measures that can be obtained from blood or muscle since this will allow the latter measures to guide drug development more reliably. As part of this work we will also build the largest ever cohort of COPD patients from whom a muscle biopsy and clinical data are available. Lastly we will study patients around the time of rehabilitation (which improves muscle function) and acute exacerbation (which worsens it) to try to identify further targets for new drugs</gtr:abstractText><gtr:technicalSummary>The overall aim of this work package is to gain new information regarding the aetiology underlying loss of skeletal muscle function, since this has a clinically relevant impact on morbidity, mortality and healthcare utilisation in Chronic Obstructive Pulmonary Disease (COPD). Key components of the program include (a) quick wins by screening material from available cohorts to assist with development decisions for available products and the development of regulatory endpoints relevant to the non-pulmonary effects of the disease, (b) direct measurement of protein synthesis using labelled amino acids and (c) extension of existing cohorts both when stable and at times of changing muscle bulk (after rehabilitation and exacerbation). Novel clinical features of the cohort will be the assessment of quadriceps strength, bulk, field test of walking performance and the obtaining of paired muscle and blood samples.

Signalling pathways to be evaluated by the consortium will include (i) Muscle cell phenotype (MHC gene expression and fibre-type, mitochondrial function, myogenic transcription factors, such as myf5, myoD, myogenin, SRF, MRTFA/B and MASTR, and mechano-sensitive regulators of transcription factor activity specifically FHL1 and FHL3 (ii) Anabolic and insulin signalling (Akt,mTOR, P70s6 kinase, 4EBP1, FOXO1, IRS-1, IRS-2 and phospho-IRS-2 and GLUT-1/GLUT-4 expression (iii) Myostatin signalling (myostatin and extracellular regulators of myostatin (follistatin, FLRG and GASP-1) by ELISA (iv)Protein degradation (MAFbx, cathepsin-L and PDK2 (mRNA by qPCR, total and phospho, protein by Western blotting), (v) metabolism; Muscle metabolites (ATP, PCr, glycogen, lactate by fluorescence), muscle pyruvate dehydrogenase complex activity pyruvate dehydrogenase kinase 2 and 4 mRNA and (vi) cellular markers of ageing. Importantly material will be made available to pharma who have offered to share the cost of these analyses as an ?in-kind contribution. 

Within the workpacakge a responsive management style will allow movement of funds so that the consortium as a whole can focus its funds to obtain maximum productivity and will have a steering committee co-chaired by academia and pharma. Externally the WP will interdigitate with WP 1,2 &amp;amp; 3 for maximum ?added-value? and more widely with the PRO-active and COPD Foundation initiatives with the aim of supporting regulatory approval for outcomes relevant to antisarcopenic drugs</gtr:technicalSummary><gtr:fund><gtr:end>2015-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1026748</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis Institutes for BioMedical Research (NIBR)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Novartis affymetrix analysis</gtr:description><gtr:id>53473EF6-43B5-4FFF-BBBB-81A5662563F2</gtr:id><gtr:impact>paper in prepartaion</gtr:impact><gtr:outcomeId>58bdbab7726046.22366386-1</gtr:outcomeId><gtr:partnerContribution>Leicester and Nottingham provided clinical data and biopsies</gtr:partnerContribution><gtr:piContribution>Under the collaboration created by COPD MAP, Novartis agreed to undertake affymetrix analysis of archive specimens held by the universities of Leicester and Nottingham

Exact cost unknown and commercially sensitive</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>GlaxoSmithKline Medicines Research Centre</gtr:department><gtr:description>TSB ERICA</gtr:description><gtr:id>63DEAD5A-3CA3-4899-9719-73EA669851B8</gtr:id><gtr:impact>Project started October 2011. no tangible outcome at time of writing</gtr:impact><gtr:outcomeId>JdnyrYy2gwB-1</gtr:outcomeId><gtr:piContribution>Co PI on new grant award</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leicester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Physics &amp; Astronomy</gtr:department><gtr:description>Stratified Exercise Interventions in Chronic Obstructive Pulmonary Disease: optimal delivery of exercise and anabolic therapies to meet individual health needs</gtr:description><gtr:id>4528D480-FF43-4404-93EE-E5343E1BB6DC</gtr:id><gtr:impact>Plan is to use same core for an MRC Cohort application</gtr:impact><gtr:outcomeId>58bdb80676cbb3.35256961-1</gtr:outcomeId><gtr:partnerContribution>Workup of proposal</gtr:partnerContribution><gtr:piContribution>This was a collaborative application submitted by Prof Steiner but including many of the partners from COPD MAP; rejected by MRC</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>affymatrix analysis of MATCH samples</gtr:description><gtr:id>7567478A-D4B1-401B-8905-4EA8E07C4370</gtr:id><gtr:impact>paper in preparation</gtr:impact><gtr:outcomeId>58bdb97fd2cd24.20843302-1</gtr:outcomeId><gtr:partnerContribution>they have undertaken affymetric analysis</gtr:partnerContribution><gtr:piContribution>COPD MAP provided clinical data and biopsies, from the Leicester site</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Cafe Scientifique</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>DB41972D-5997-4FC4-B130-4A2823F5E19A</gtr:id><gtr:impact>30 members of the public attended a presentation which sparked questions and discussion afterwards

Good positive feedback and future events to be arranged</gtr:impact><gtr:outcomeId>mTXjiVuX71s</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>249815</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC NIRG</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>97DB5D8A-7A97-4467-9BA5-4B943B76ADEF</gtr:id><gtr:outcomeId>nij7FBJ5gty0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Pulmonary Rehabilitation Quality Standards</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FFF221A2-9C0E-4933-9EC1-D3FBEA4BCEEA</gtr:id><gtr:impact>I co-chair the British Thoracic Society Quality Standards Committee with responsibility for drafting and agreeing the publication of the standards. These standards will provide guidance for commissioners and providers on improving quality in pulmonary rehabilitation provision</gtr:impact><gtr:outcomeId>dBa2SZzSJHH</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ERS taskforce on Nutrition in COPD</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>F1C47FDF-8C31-4645-AF98-A4367EC47D98</gtr:id><gtr:outcomeId>eosLrJxPfj7</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>National Clinical COPD audit</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3CA71A82-9FA5-40A6-8E87-B2012E123D17</gtr:id><gtr:outcomeId>U8CYdY8jqZF</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>COPD Foundation exercise CBQC</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>197AA281-7051-49D0-9959-2D35FF52CB87</gtr:id><gtr:impact>Based on expertise gathered by this and other consortia, Professor Polkey is a representative on the COPD foundation CBQC working group seeking to qualify exercise as an FDA acceptable outcome</gtr:impact><gtr:outcomeId>LreFXy4HtAM</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ATS/ARS statement on skeletal muscle dysfunction in COPD</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>B24A9289-C82F-4280-BE66-5B88E42BB742</gtr:id><gtr:outcomeId>jCf6vbEm4B7</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3EBC18A0-19DC-44B8-8A28-E8FEB158FB10</gtr:id><gtr:title>Fibrocyte trafficking in patients with chronic obstructive asthma and during an acute asthma exacerbation.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa93aa452bfcd1b752d72dd489b66ab5"><gtr:id>aa93aa452bfcd1b752d72dd489b66ab5</gtr:id><gtr:otherNames>Wang CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>5675dd3019181</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A686B006-EC22-49D0-BC68-0226313011F3</gtr:id><gtr:title>Impaired muscle mitochondrial density and/or function: a COPD-specific mitochondropathy or simply deconditioning?</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ddd71d5e6b55da695fb281b937f03b11"><gtr:id>ddd71d5e6b55da695fb281b937f03b11</gtr:id><gtr:otherNames>Lazaar AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>pm_13691_21_23115308</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE22A639-589D-452E-87DE-D0629DBECD28</gtr:id><gtr:title>Circulating miRNAs from imprinted genomic regions are associated with peripheral muscle strength in COPD&amp;nbsp;patients.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21f6a74a058e015d4e6791267279c0be"><gtr:id>21f6a74a058e015d4e6791267279c0be</gtr:id><gtr:otherNames>Lee JY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>5a2fd23ba0b8d6.32684283</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>154C52B4-70F3-4BD8-8555-3B5CF07ECDA6</gtr:id><gtr:title>MiR-181a: a potential biomarker of acute muscle wasting following elective high-risk cardiothoracic surgery.</gtr:title><gtr:parentPublicationTitle>Critical care (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0240e8bde5f712e742285d05c0a644ea"><gtr:id>0240e8bde5f712e742285d05c0a644ea</gtr:id><gtr:otherNames>Bloch SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1364-8535</gtr:issn><gtr:outcomeId>5675e2b303da3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A183CC6B-B234-4331-AE9E-6BA5379DF6AA</gtr:id><gtr:title>Prospects for the development of effective pharmacotherapy targeted at the skeletal muscles in chronic obstructive pulmonary disease: a translational review.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3552568001d14568f5c8ac4a08b4b36"><gtr:id>d3552568001d14568f5c8ac4a08b4b36</gtr:id><gtr:otherNames>Steiner MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>pm_13691_21_22561528</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76FF9C98-D923-4CC4-93E2-E1BF5921DCD4</gtr:id><gtr:title>Increased expression of GDF-15 may mediate ICU-acquired weakness by down-regulating muscle microRNAs.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0240e8bde5f712e742285d05c0a644ea"><gtr:id>0240e8bde5f712e742285d05c0a644ea</gtr:id><gtr:otherNames>Bloch SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>doi_55f9859857db176a</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1001362</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>9A8BEDCC-D902-4C9A-8CCF-C974265EA3FB</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.4  Surveillance and distribution</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>5C2ACE0A-A29E-4DCC-9F5A-B00BFAB172B9</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>4.4  Population screening</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>